2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK Apoptosis
  3. Antibody-Drug Conjugates (ADCs) VEGFR Apoptosis
  4. Bevacizumab vedotin

Bevacizumab vedotin is an antibody-drug conjugate (ADC). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis (Apoptosis), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer.

For research use only. We do not sell to patients.

Bevacizumab vedotin

Bevacizumab vedotin Chemical Structure

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Bevacizumab vedotin Related Antibodies

Top Publications Citing Use of Products

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Bevacizumab vedotin is an antibody-drug conjugate (ADC). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis (Apoptosis), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer[1].

In Vitro

Bevacizumab vedotin (1 mg; 72-120 h) exhibits high serum stability[1].
Bevacizumab vedotin (30-165 min) rapidly and completely releases its MMAE payload under the mediation of cathepsin B[1].
Bevacizumab vedotin (0-10 μg/mL; 48 h) potently inhibits the proliferation of U87, HepG2 and MCF-7 cells, with IC50 values of 14.1712 μg/mL, 0.6483 μg/mL and 0.1442 μg/mL, respectively[1].
Bevacizumab vedotin (1 μg/mL; 48 h) induces apoptosis in U87, HepG2 and MCF-7 cells after 48 h of treatment[1].
Treatment with Bevacizumab vedotin (0.1-20 μg/mL; 48 h) induces G1-phase cell cycle arrest in U87 and HepG2 cells[1].
Bevacizumab vedotin (0.01-0.1 μg/mL; 12-48 h) inhibits the migration of MCF-7 cells in a concentration- and time-dependent manner, and downregulates the expression of VEGF-A in MCF-7 cells[1].
Bevacizumab vedotin (0.1-1 μg/mL; 4-48 h) exhibits anti-angiogenic activity, reduces tube formation (junctions and branches) in HUVECs, downregulates VEGF-A expression, and upregulates VEGFR-2 expression in HUVECs[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bevacizumab vedotin Related Antibodies

Cell Proliferation Assay[1]

Cell Line: U87 , HepG2 , MCF-7 cells
Concentration: 0, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 5, 10 μg/mL
Incubation Time: 48 h
Result: Inhibited proliferation of all three cell lines.
Reached an IC50 of 14.1712 μg/mL for U87 cells.
Reached an IC50 of 0.6483 μg/mL for HepG2 cells.
Reached an IC50 of 0.1442 μg/mL for MCF-7 cells.

Apoptosis Analysis[1]

Cell Line: U87 , HepG2 , MCF-7 cells
Concentration: 1 μg/mL
Incubation Time: 48 h
Result: Promoted apoptosis in all three cell lines.
Achieved a pro-apoptotic rate of 113% relative to the control group for U87 cells.
Achieved a pro-apoptotic rate of 304% relative to the control group for HepG2 cells.
Achieved a pro-apoptotic rate of 288% relative to the control group for MCF-7 cells.

Cell Cycle Analysis[1]

Cell Line: U87 , HepG2 cells
Concentration: 0.1-20 μg/mL
Incubation Time: 48 h
Result: Induced G1 phase cell cycle arrest in U87 and HepG2 cells.

Cell Migration Assay [1]

Cell Line: MCF-7 cells
Concentration: 0, 0.01, 0.02, 0.05, 0.1 μg/mL
Incubation Time: 0 h, 12 h, 24 h, 36 h and 48 h
Result: Enhanced concentration-dependent inhibition of MCF-7 cell migration with increasing incubation time.

Western Blot Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.01, 0.05, 0.1 μg/mL
Incubation Time: 48 h
Result: Caused concentration-dependent downregulation of VEGF-A expression in MCF-7 cells.

Western Blot Analysis[1]

Cell Line: HUVEC cells
Concentration: 0.1, 0.5, 1 μg/mL
Incubation Time: 48 h
Result: Caused concentration-dependent downregulation of VEGF-A expression in HUVEC cells.
Caused concentration-dependent upregulation of VEGFR-2 expression in HUVEC cells.
Molecular Weight

149114 (average)

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Bevacizumab vedotin]
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bevacizumab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bevacizumab vedotinAntibody-Drug Conjugates (ADCs)VEGFRApoptosisAntibody-Drug ConjugatesVascular endothelial growth factor receptorAntibody-drug Conjugategliomahepatocellular carcinomabreast cancerU87 cellsHepG2 cellsMCF-7 cells
Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bevacizumab vedotin
Cat. No.:
HY-185208
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.